This page provides educational information on cellular ageing and mechanisms that are being studied in relation to eye health. The content is general in nature and is meant to complement – never replace – ophthalmological assessment and standard therapies.
Senescent cells – sometimes referred to as “zombie cells” in popular science – tend to accumulate with age and may contribute to chronic low‑grade inflammation. Click the side boxes to see a simplified representation of how different factors are discussed in the literature in relation to damaged and healthy cells.
“Senolytics” refers to molecules or strategies that aim, in theory, to selectively affect senescent cells. This is an evolving research area, largely supported by preclinical data, and does not currently provide robust evidence for routine clinical protocols in eye disease.
“Senomorphics” refers to strategies that aim to lessen the impact of senescent cells without necessarily eliminating them. The focus is on SASP, the set of molecules they release, which may contribute to low‑grade inflammation.
Over time, and under oxidative and metabolic stress, some damaged cells may escape apoptosis and acquire a senescent phenotype. In this context, SASP (Senescence‑Associated Secretory Phenotype) describes a pattern of secreted mediators that, according to preclinical data, may influence the course of degenerative conditions, including ocular diseases.
Natural‑origin substances such as Fisetin, Quercetin and others (for example Piperlongumine) are frequently mentioned in research as candidates with possible senolytic activity. Most evidence comes from cell and animal models and is not sufficient to recommend standardised protocols or self‑directed supplement use in ophthalmology.
Compounds such as Resveratrol, Luteolin or certain antioxidant vitamins are being studied for their potential to modulate signalling pathways, including NF‑κB, and influence SASP. These findings should be viewed as research insights rather than direct treatment recommendations for eye diseases.
Curcumin is often cited as an example of a multi‑target compound with effects on various inflammatory and signalling pathways. Again, most data come from experimental contexts; any use as a supplement requires individual risk–benefit evaluation and consideration of possible drug interactions.
The scientific literature discusses the possibility that lifestyle interventions – such as physical activity, regular sleep patterns and, in selected cases, structured fasting protocols – may stimulate autophagy, the cellular “recycling” process. These hypotheses cannot replace specific treatments for ocular disease and must always be considered within a personalised medical plan.
The information on this page is based on preclinical and observational studies regarding cellular senescence and potential effects of senolytic and senomorphic strategies, including in eye‑related research. Currently, there are no universally validated, large‑scale clinical protocols supporting these approaches as primary treatments for ocular diseases. The content is for educational purposes only, does not provide therapeutic regimens and does not replace eye examinations, medical advice or conventional therapies. Any decision regarding supplements, lifestyle changes or other interventions must be made together with healthcare professionals.